genentech inc said filed suit against food and drug administration district court for district columbia over unresolved issue relating genetically engineered human growth hormone issue said genentech whether eli lilly and recombinant human growth hormone and its new recombinant growth hormone same drug both drugs under review fda since 1985 genentech has been marketing protropin recombinant human growth hormone for treating abnormally short children biotechnology concern said has right seven years exclusive marketing for protropin granted orphan drug status fda orphan drugs special category drugs used treat rare diseases genentech said suit seeks clarification constitutes drug under standards orphan drug act suggested without clarification companies develop orphan drugs may not recover development costs during period marketing exclusivity said lilly growth hormone and its new growth hormone differ slightly and produced different processes reuter 